普赛睿致力于开发以新型单克隆抗体和CAR-T为基础的癌症免疫治疗药物。通过与杰出科研者的紧密合作,我们对拥有巨大潜力的生物项目进行深度孵化和推进,以期这些项目能够早日进入临床甚至市场。目前我们拥有4个处于临床前期阶段的优质项目。

目前的项目及其进行情况

Protheragen's fully human monoclonal antibody/CAR-T pipelines

Protheragen has been striving to develop pipelines based on novel monoclonal antibody and CAR-T for cancer immunotherapy. Through close collaboration with distinguished scientists, we have promoted biotherapeutics candidates of great potential from discovery to preclinical studies and clinical trials. The current four pipelines are in preclinical phase and have all shown promising results.

Protheragen's fully human monoclonal antibody/CAR-T pipelines

Our current pipelines

Program Indication Discovery Optimisation Preclinical Clinical Phase I Clinical Phase II Clinical Phase III
Pro-001 Ovarian Cancer
Pro-002 Breast Cancer
Pro-003 Ovarian Cancer
Pro-004 Breast Cancer
联系我们

地址:中国(四川)自由贸易试验区成都高新区天府五街200号5号楼A区
电话:028-88612106
邮箱:info@psrbiopharma.com


关注普赛睿微信公众号

我要咨询